Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 8/20 | 0.54 |
| ▸ | GSK3A | P49840 | 2/20 | 0.52 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.52 |
| ▸ | NT5E | P21589 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | PNP | P00491 | 1/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.46 |
| ▸ | KRAS | P01116 | 1/20 | 0.46 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17936222 | 0.92 | HINT1 (0.64) | HINT1GSK3ARPS6KA3MAPK14NT5E | |
| SCHEMBL6468412 | 0.92 | HINT1 (0.64) | HINT1GSK3ARPS6KA3MAPK14NT5E | |
| SCHEMBL881724 | 0.88 | NT5E (0.57) | HINT1GSK3ARPS6KA3MAPK14NT5E | |
| SCHEMBL7063499 | 0.88 | HINT1 (0.53) | HINT1GSK3ARPS6KA3MAPK14NT5E | |
| SCHEMBL7063503 | 0.88 | HINT1 (0.53) | HINT1GSK3ARPS6KA3MAPK14NT5E | |
| SCHEMBL5505060 | 0.84 | HINT1 (0.47) | HINT1GSK3ARPS6KA3MAPK14NT5E | |
| SCHEMBL23211677 | 0.83 | POLB (0.59) | HINT1GSK3ARPS6KA3MAPK14NT5E | |
| SCHEMBL20534766 | 0.83 | POLB (0.59) | HINT1GSK3ARPS6KA3MAPK14NT5E | |
| SCHEMBL22327460 | 0.83 | POLB (0.59) | HINT1GSK3ARPS6KA3MAPK14NT5E | |
| SCHEMBL17198349 | 0.81 | HPGD (0.64) | HINT1GSK3ARPS6KA3MAPK14NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| WO-2015161137-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | RB1, NSUN2, METTL3 | HINT1 1204/4885GSK3A 315/4885RPS6KA3 793/4885 |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | RB1, NSUN2, METTL3 | HINT1 1201/4885GSK3A 315/4885RPS6KA3 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.